Disease-modifying antirheumatic drugs other than methotrexate in rheumatoid arthritis and seronegative arthritis

Current Opinion in Rheumatology

Volumn 20, Issue 3, 2008, Pages 251-256

  Nandi, Pradip ^a   Kingsley, Gabrielle H ^b,c   Scott, David L ^c  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITAL LEWISHAM   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Ciclosporin; Hydroxychloroquine; Leflunomide; Rheumatoid arthritis; Sulfasalazine

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; PENICILLAMINE; PREDNISOLONE; SALAZOSULFAPYRIDINE; STEROID;

BACTERIAL ARTHRITIS; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; COMORBIDITY; DIABETES MELLITUS; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; LUNG DISEASE; MONOTHERAPY; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY CONTROL; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; RISK; UNSPECIFIED SIDE EFFECT;

ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; DRUG THERAPY, COMBINATION; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 41649109238     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e3282fb7caa     Document Type: Review

References (38)

1. Donahue KE, Gartlehner G, Jonas DE, et al. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 2008; 148:124-134. Key systematic review of DMARD therapy in RA. Its conclusions are controversial but it is well put together and is a convincing argument in favour of more conservative treatments based on DMARDs.
2. Finckh A, Liang MH, van Herckenrode CM, de Pablo P. Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: a meta-analysis. Arthritis Rheum 2006; 55:864-872.
3. Suarez-Almazor ME, Belseck E, Shea B, et al. Antimalarials for treating rheumatoid arthritis. Cochrane Database Syst Rev 2000; 4:CD000959.
4. Das SK, Pareek A, Mathur DS, et al. Efficacy and safety of hydroxychloroquine sulphate in rheumatoid arthritis: a randomized, double-blind, placebo controlled clinical trial: an Indian experience. Curr Med Res Opin 2007; 23:2227-2234.
5. Sokka T, Kautiainen H, Toloza S, et al. QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries. Ann Rheum Dis 2007; 66:1491-1496. Major comparative study of current treatments used in RA across countries and centres. Shows the marked diversity of care.
6. Gibofsky A, Palmer WR, Goldman JA, et al. Real-world utilization of dmards and biologics in rheumatoid arthritis: the radius (rheumatoid arthritis disease-modifying antirheumatic drug intervention and utilization study) study. Curr Med Res Opin 2006; 22:169-183.
7. Andrianakos A, Trontzas P, Christoyannis F, et al. Prevalence and management of rheumatoid arthritis in the general population of Greece: the ESORDIG study. Rheumatology 2006; 45:1549-1554.
8. Grijalva CG, Chung CP, Arbogast PG, et al. Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (dmards) in patients with rheumatoid arthritis. Med Care 2007; 45:S66-S76.
9. Lu CY, Williams KM, Day RO. Has the use of disease-modifying antirheumatic drugs changed as a consequence of controlled access to high-cost biological agents through the pharmaceutical benefits scheme? Intern Med J 2007;37:601-606.
10. Soderlin MK, Lindroth Y, Jacobsson LT. Trends in medication and health-related quality of life in a population-based rheumatoid arthritis register in Malmo, Sweden. Rheumatology 2007; 46:1355-1358.
11. Kahn KL, MacLean CH, Liu H, et al. Application of explicit process of care measurement to rheumatoid arthritis: moving from evidence to practice. Arthritis Rheum 2006; 55:884-891.
12. Meyer O, de Bandt M, Berthelot JM, et al. Clinical practice format for choosing a second-line disease modifying antirheumatic drug in early rheumatoid arthritis after failure of 6 months' first-line dmard therapy. Joint Bone Spine 2007; 74:73-78.
13. Fraenkel L, Rabidou N, Dhar R. Are rheumatologists' treatment decisions influenced by patients' age? Rheumatology 2006; 45:1555-1557.
14. Boers M, Verhoeven AC, Markusse HM, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997; 350:309-318.
15. Choy EH, Smith CM, Farewell V, et al. Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis. Ann Rheum Dis (in press). Shows benefit of intensive combination therapy in early RA.
16. Hetland ML, Stengaard-Pedersen K, Junker P, et al. Aggressive combination therapy with intraarticular glucocorticoid injections and conventional dmards in early rheumatoid arthritis two year clinical and radiographic results from the CIMESTRA study. Ann Rheum Dis (in press). Also shows benefit of intensive combination therapy in early RA.
17. Capell HA, Madhok R, Porter DR, et al. Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study. Ann Rheum Dis 2007; 66:235-241. Another trial that shows the benefit of combination therapy with two DMARDs in early RA.
18. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 2007; 146:406-415. Definitive study of treatment strategies in early RA.
19. Hetland ML, Stengaard-Pedersen K, Junker P, et al. Combination treatment with methotrexate, cyclosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis: an investigator-initiated, multicenter, randomized, double-blind, parallel-group, placebo-controlled study. Arthritis Rheum 2006; 54:1401-1409.
20. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005; 52:3381-3390.
21. van der Kooij SM, de Vries-Bouwstra JK, Goekoop-Ruiterman YP, et al. Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score. Ann Rheum Dis 2007; 66:1356-1362.
22. Proudman SM, Keen HI, Stamp LK, et al. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use. Semin Arthritis Rheum 2007; 37:99-111.
23. Verschueren P, Esselens G, Westhovens R. Daily practice effectiveness of a step-down treatment in comparison with a tight step-up for early rheumatoid arthritis. Rheumatology 2008; 47:59-64.
24. Schoels M, Kapral T, Stamm T, et al. Step-up combination versus switching of nonbiological disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a retrospective observational study. Ann Rheum Dis 2007; 66:1059-1065.
25. Ravindran V, Scott DL, Choy EH. A systematic review and meta-analysis of efficacy and toxicity of disease modifying antirheumatic drugs and biologic agents for psoriatic arthritis. Ann Rheum Dis (in press).
26. Marzo-Ortega H, Green MJ, Keenan AM, et al. A randomized controlled trial of early intervention with intraarticular corticosteroids followed by sulfasalazine versus conservative treatment in early oligoarthritis. Arthritis Rheum 2007; 57:154-160.
27. Bernatsky S, Hudson M, Suissa S. Antirheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology 2007; 46:1157-1160.
28. Edwards CJ, Cooper C, Fisher D, et al. The importance of the disease process and disease-modifying antirheumatic drug treatment in the development of septic arthritis in patients with rheumatoid arthritis. Arthritis Rheum 2007; 57:1151-1157.
29. Jenks KA, Stamp LK, O'Donnell JL, et al. Leflunomide-associated infections in rheumatoid arthritis. J Rheumatol 2007; 34:2201-2203.
30. Scott DL. Interstitial lung disease and disease modifying antirheumatic drugs. Lancet 2004; 363:1239-1240.
31. Martin N, Innes JA, Lambert CM, et al. Hypersensitivity pneumonitis associated with leflunomide therapy. J Rheumatol 2007; 34:1934-1937.
32. Suissa S, Hudson M, Ernst P. Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. Arthritis Rheum 2006; 54:1435-1439.
33. Ju JH, Kim SI, Lee JH, et al. Risk of interstitial lung disease associated with leflunomide treatment in Korean patients with rheumatoid arthritis. Arthritis Rheum 2007; 56:2094-2096.
34. van Halm VP, Nurmohamed MT, Twisk JW, et al. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther 2006; 8:R151.
35. Solomon DH, Avorn J, Katz JN, et al. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54:3790-3798.
36. Wasko MC, Hubert HB, Lingala VB, et al. Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA 2007; 298:187-193.
37. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Patient preferences for treatment: report from a randomised comparison of treatment strategies in early rheumatoid arthritis (BeSt trial). Ann Rheum Dis 2007; 66:1227-1232.
38. van Tuyl LH, Plass AM, Lems WF, et al. Why are Dutch rheumatologists reluctant to use the cobra treatment strategy in early rheumatoid arthritis? Ann Rheum Dis 2007; 66:974-976. Fascinating insights into why rheumatologists are reluctant to use combination therapy.